{"nctId":"NCT03537651","briefTitle":"A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation","startDateStruct":{"date":"2018-04-25","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":130,"armGroups":[{"label":"TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: TEZ/IVA","Drug: IVA"]}],"interventions":[{"name":"TEZ/IVA","otherNames":["VX-661/VX-770","tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed the Week 24 Visit in Study 113 Part B or the Week 8 Visit in Study 115\n* Eligible CFTR Mutation\n\nExclusion Criteria:\n\n* Pregnant and nursing females\n* History of poor compliance with study drug and/or procedures in a previous study as deemed by the investigator\n* Ongoing participation in another study with investigational drug\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change in Lung Clearance Index2.5 (LCI2.5) for 115/116 FAS (TEZ/IVA Group)","description":"The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change in LCI2.5 for 113B/116 LCI FAS","description":"The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.04","spread":"1.73"}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change in Sweat Chloride (SwCl) for 115/116 FAS (TEZ/IVA Group)","description":"Sweat samples were collected using an approved collection device.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change in SwCl for 113B/116 FAS","description":"Sweat samples were collected using an approved collection device.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 115/116 FAS (TEZ/IVA Group)","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with CF. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change in CFQ-R Respiratory Domain Score for 113B/116 FAS","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with CF. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change in Body Mass Index (BMI) for 115/116 FAS (TEZ/IVA Group)","description":"BMI was defined as weight in kilograms (kg) divided by squared height in meters (m\\^2).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Absolute Change in BMI for 113B/116 FAS","description":"BMI was defined as weight in kg divided by m\\^2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":130},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Upper respiratory tract infection","Nasopharyngitis","Oropharyngeal pain"]}}}